Přihlásit se Zaregistrujte se zdarma

Návratnost kapitálu společnosti Cotinga Pharmaceuticals

Jaká je hodnota metriky Návratnost kapitálu společnosti Cotinga Pharmaceuticals?

Hodnota metriky Návratnost kapitálu společnosti Cotinga Pharmaceuticals, Inc. je 0.00%

Jaká je definice metriky Návratnost kapitálu?



Return on capital employed (ROCE) je finanční ukazatel, který měří rentabilitu společnosti a efektivitu společnosti ve využívání vlastního kapitálu.

Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.

ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.

Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.

Návratnost kapitálu společností v sektoru Health Care sektor na TSXV ve srovnání se společností Cotinga Pharmaceuticals

Čemu se věnuje společnost Cotinga Pharmaceuticals?

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.

Firmy s metrikou návratnost kapitálu podobnou společnosti Cotinga Pharmaceuticals